← board
ANIP
distress 2/10 · well-funded / low risk$76.82-1%today-22% from 52w high
Revenue
$237M
Liquidity
$311M
Runway
—
Shares 1y
-80%
Price & events
-10.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-6.2%
1W
-7.4%
1M
-1.6%
3M
-7.4%
6M
+14.8%
1Y
+18.7%
2Y
+131.9%
5Y
+154.2%
All
Overview
- Market Cap
- $1.88B
- Enterprise Value
- $1.85B
- Volume
- 8.05K
- 52 Week Range
- $63.35 – $98.81
- Total Shares
- 24.42M
- Float Shares
- 19.42M
- Short %
- 18.48%
- % Held by Insiders
- 5.54%
- % Held by Institutions
- 110.38%
- RVOL
- 0.03x
- Beta
- 0.43
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026-08-07Estimated 45%earningsEarningsEarnings releaseyahoo
- January 13, 2026conferencedata presentationsecondaryPresident & CEO presents at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- 2025-07-29trial discontinuedJury verdict: no damages awarded to ANI on unjust enrichment counterclaim; ANI will challenge.SEC 8-K
- May 20, 2025conferencedata presentationsecondaryANI Pharmaceuticals presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference.SEC 8-K
- 2024-09-16partnershipCompleted acquisition of Alimera Sciences, Inc.SEC 8-K
Approved drugs (14)
- TESTOSTERONETESTOSTERONE2012 · Discontinued
- LUVOXFLUVOXAMINE MALEATE2007 · Prescription
- VEREGENSINECATECHINS2006 · Prescription
- INNOPRAN XLPROPRANOLOL HYDROCHLORIDE2003 · Prescription
- ATACAND HCTCANDESARTAN CILEXETIL2000 · Prescription
- ATACANDCANDESARTAN CILEXETIL1998 · Prescription
- PANDELHYDROCORTISONE PROBUTATE1997 · Discontinued
- ARIMIDEXANASTROZOLE1995 · Prescription
- CASODEXBICALUTAMIDE1995 · Prescription
- OXISTATOXICONAZOLE NITRATE1992 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $110 (+43% upside) · 8 analysts
- 2026-07-17Canaccord GenuityHold
- 2026-07-10GuggenheimBuy
- 2026-01-16GuggenheimBuy
- 2025-12-09BarclaysOverweight
- 2025-11-10GuggenheimBuy
- 2025-10-09Truist SecuritiesHold
Competitors
- none identified
Recent news
- 2026-07-21ANI Pharmaceuticals (ANIP) GC has 2,466 shares withheld for taxes on RSU vesting - Stock Titan
- 2026-07-20ANI Pharmaceuticals (ANIP) On Strong ILUVIEN Trial Data Is The Stock A Bargain - Sahm
- 2026-07-19How Positive SYNCHRONICITY Trial Data for ILUVIEN at ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story - Sahm
- 2026-07-18Is ANI Pharmaceuticals Inc (ANIP) a Bargain After 3.3% Drop? GF Value Says Undervalued - GuruFocus
- 2026-07-14Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
- 2026-07-14ANI Pharmaceuticals (ANIP) counsel sells 500 shares under 10b5-1 plan - Stock Titan
- 2026-07-11ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity? - Sahm
- 2026-07-10ANI Pharmaceuticals Inc (ANIP) Institutional Confidence - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.